Cipla
Cipla Performance
Day Range
- Low 1,197.00
- High 1,225.00
52 Week Range
- Low 852.00
- High 1,283.55
- Open Price1,206.00
- Previous Close1,205.20
- Volume1269290
Start SIP in Cipla
Start SIPCipla Investment Rating
-
Master Rating:
-
Cipla has an operating revenue of Rs. 24,556.43 Cr. on a trailing 12-month basis. An annual revenue growth of 5% is not great, Pre-tax margin of 18% is great, ROE of 11% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 12% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It has recently broken out of a base in its weekly chart and is trading around -5% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 92 which is a GREAT score indicating consistency in earnings, a RS Rating of 44 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 68 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Indicator | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
---|---|---|---|---|---|---|---|
Oper Rev Qtr Cr | 4,167 | 3,858 | 3,486 | 3,541 | 3,746 | 3,070 | 2,882 |
Operating Expenses Qtr Cr | 3,286 | 3,114 | 3,094 | 2,961 | 3,090 | 2,300 | 2,559 |
Operating Profit Qtr Cr | 1,379 | 1,205 | 800 | 938 | 1,061 | 857 | 388 |
Depreciation Qtr Cr | 180 | 136 | 162 | 130 | 176 | 107 | 117 |
Interest Qtr Cr | 8 | 0 | 10 | 7 | 8 | 2 | 6 |
Tax Qtr Cr | 367 | 331 | 206 | 250 | 265 | 221 | 105 |
Net Profit Qtr Cr | 1,030 | 895 | 355 | 679 | 720 | 759 | 653 |
Cipla Technicals
EMA & SMA

- Bullish Moving Average
- ___
- 15
- Bearish Moving Average
- ___
- 1
- 20 Day
- ₹1,216.20
- 50 Day
- ₹1,206.64
- 100 Day
- ₹1,174.78
- 200 Day
- ₹1,122.48
- 20 Day
- ₹1,225.53
- 50 Day
- ₹1,200.01
- 100 Day
- ₹1,196.55
- 200 Day
- ₹1,069.01
Cipla Resistance and Support
Resistance | |
---|---|
First Resistance | 1,232.87 |
Second Resistance | 1,242.93 |
Third Resistance | 1,260.87 |
RSI | 52.11 |
MFI | 52.42 |
MACD Single Line | 3.03 |
MACD | 1.03 |
Support | |
---|---|
First Resistance | 1,204.87 |
Second Resistance | 1,186.93 |
Third Resistance | 1,176.87 |
Cipla Delivery and Volume
Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
---|---|---|---|
Day | 1,350,526 | 74,386,972 | 55.08 |
Week | 1,650,520 | 109,396,466 | 66.28 |
1 Month | 1,870,309 | 94,357,106 | 50.45 |
6 Month | 1,863,361 | 91,267,419 | 48.98 |
Cipla Result Highlights
Cipla Synopsis
NSE-Medical-Generic Drugs
Cipla is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 15790.60 Cr. and Equity Capital is Rs. 161.43 Cr. for the Year ended 31/03/2023. Cipla Ltd. is a Public Limited Listed company incorporated on 17/08/1935 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1935PLC002380 and registration number is 002380.Market Cap | 98,755 |
Sales | 16,776 |
Shares in Float | 54.09 |
No of funds | 953 |
Yield | 0.69 |
Book Value | 3.95 |
U/D Vol ratio | 1.3 |
LTDebt / Equity | |
Alpha | 0.03 |
Beta | 0.5 |
Cipla
Owner Name | Sep-23 | Jun-23 | Mar-23 | Dec-22 |
---|---|---|---|---|
Promoters | 33.47% | 33.47% | 33.55% | 33.61% |
Mutual Funds | 16.48% | 15.35% | 15% | 14.09% |
Insurance Companies | 5.25% | 6.26% | 4.74% | 4.85% |
Foreign Portfolio Investors | 25.74% | 25.49% | 27.42% | 28.39% |
Financial Institutions/ Banks | 0.04% | 0.01% | 0.11% | 0.11% |
Individual Investors | 14.45% | 14.66% | 14.85% | 14.72% |
Others | 4.57% | 4.76% | 4.33% | 4.23% |
Cipla Management
Name | Designation |
---|---|
Dr. Y K Hamied | Chairman |
Mr. M K Hamied | Vice Chairman |
Ms. Samina Hamied | Executive Vice Chairman |
Mr. Umang Vohra | Managing Director & Global CEO |
Mr. S Radhakrishnan | Non Exe.Non Ind.Director |
Mr. Ashok Sinha | Independent Director |
Mr. P R Ramesh | Independent Director |
Mr. Robert Stewart | Independent Director |
Dr. Mandar Vaidya | Independent Director |
Mr. Adil Zainulbhai | Independent Director |
Ms. Punita Lal | Independent Director |
Cipla Forecast
Price Estimates
Cipla Corporate Action
Date | Purpose | Remarks |
---|---|---|
2023-10-27 | Quarterly Results | |
2023-07-26 | Quarterly Results | |
2023-05-12 | Audited Results & Final Dividend | |
2023-01-25 | Quarterly Results | |
2022-11-04 | Quarterly Results |
Date | Purpose | Remarks |
---|---|---|
2023-07-21 | FINAL | Rs.8.50 per share(425%)Final Dividend |
2022-08-10 | FINAL | Rs.5.00 per share(250%)Dividend |
About Cipla
Cipla FAQs
What is Share Price of Cipla ?
Cipla share price is ₹1,222 As on 07 December, 2023 | 19:10
What is the Market Cap of Cipla ?
The Market Cap of Cipla is ₹98722.8 Cr As on 07 December, 2023 | 19:10
What is the P/E ratio of Cipla ?
The P/E ratio of Cipla is 28.6 As on 07 December, 2023 | 19:10
What is the PB ratio of Cipla ?
The PB ratio of Cipla is 4.2 As on 07 December, 2023 | 19:10
Is it the right time to invest in Cipla?
Cipla may be the correct pick right now for investors searching for value buys of quality stocks with a longer time horizon. Cipla comes with a HOLD recommendation from the analyst. Cipla has a trailing 12-month operating revenue of INR 20,799.29 crore. Annual revenue growth of 11% is strong, the pre-tax margin of 17% is excellent, and ROE of 13% is excellent. The company has a debt-to-equity ratio of 7%, which indicates a stable balance sheet. Institutional holding has gone up in the last reported quarter is a positive sign.
Is Cipla an Indian company?
Cipla Limited, headquartered in Mumbai, India, is an Indian multinational pharmaceutical corporation. Cipla primarily produces drugs for the treatment of respiratory, cardiovascular, arthritis, diabetes, weight loss, and depression, as well as other medical disorders.
Who is the CEO of Cipla?
Umang Vohra has been the CEO of Cipla since 1 September 2016.
What is Cipla's stock price CAGR?
Cipla's stock price CAGR over ten years is 11%, five years is 10%, three years is 20%, and one year is 22% percent.
How to buy Cipla Ltd. shares?
You can easily buy the shares of Grasim Industries Ltd. by registering at 5Paisa and setting up a Demat Account in your name to start trading.